Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
European Journal of Medicinal Chemistry|May 2, 2016
Alkyne-substituted diminazene as G-quadruplex binders with anticancer activitiesChanghao Wang, Brandon Carter-Cooper, Yixuan Du, et al.
ACS Medicinal Chemistry Letters|May 17, 2011
Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring SystemAtul Kondaskar, Shilpi Kondaskar, Raj Kumar, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2019
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimationSunil Adige, Rena G Lapidus, Brandon A Carter-Cooper, et al.
Cancers|August 27, 2021
DUOX2, a New Biomarker for Disseminated Gastric Cancer's Response to Low Dose Radiation in MicePalak R Parekh, Eduardo Solano-Gonzalez, Mariana B Martins, et al.
Ebiomedicine|January 29, 2019
Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in miceN Naganna, Clement Opoku-Temeng, Eun Yong Choi, et al.
Blood Advances|February 9, 2021
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclaxBlake S Moses, Samantha McCullough, Jennifer M Fox, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2022
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteasesNadire Duru, Nisha R Pawar, Erik W Martin, et al.
Cancers|March 6, 2019
The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and MetastasisSenthilmurugan Ramalingam, Vidya P Ramamurthy, Lalji K Gediya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid LeukemiaMaria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Pageof 7